A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT)

Protocol No
ALEXION-ALXN1210-TMA-313
Principal Investigator
James Jerkins
Phase
III
Summary
This project is being done to see if a drug called ravulizumab will treat TMA after HSCT by blocking complement activity.
Description
Ravulizumab in TMA after HSCT
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category
Hematologic/Blood Related Cancers
ClinicalTrials.gov
go to website